PRP for Patellar Tendinopathy: Does It Beat Needling?

Leukocyte-poor platelet-rich plasma (LP-PRP) has a plausible sales pitch for jumper's knee: concentrate platelets, inject their growth factors into a poorly vascularized tendon, and help it heal. The clinical evidence is less accommodating. In the best current comparison of injection options, LP-PRP produced modest pain relief at six months but did not significantly improve the functional score most relevant to sport participation. In a small multicenter randomized trial of patients whose symptoms had already resisted conservative care, adding LP-PRP to exercise did not beat dry needling plus the same exercise program.

That does not make LP-PRP useless or prove it never helps an individual patient. It means its added value over mechanical needling and progressive loading remains unproven—and the price premium needs a better defense than biological plausibility.

Where LP-PRP ranks among injections

A 2025 network meta-analysis by Wang et al. pooled 19 randomized controlled trials of injection strategies for patellar tendinopathy. A network meta-analysis compares treatments that have not always been tested head-to-head, using the web of available trial comparisons. That makes it useful for ranking options, but it also means its conclusions depend on whether the linked studies enrolled comparable patients and used sufficiently similar protocols.

At the six-month time point, the analysis found that LP-PRP alone did not significantly improve VISA-P scores versus non-injection conservative treatment. VISA-P is a 0-to-100 questionnaire covering pain, function, and sports participation; it is more useful than pain alone when the question is whether an athlete can tolerate tendon loading again.

LP-PRP did produce a statistically significant pain benefit on the visual analog scale: standardized mean difference (SMD) −0.71, 95% confidence interval −1.31 to −0.12, p=0.02. That is a symptom signal, not proof of restored tendon capacity. Multiple dry-needling sessions ranked better for pain in the same analysis, with an SMD of −1.78 (95% CI −2.56 to −1.00, p<0.01).

The top VISA-P rankings belonged to polidocanol sclerotherapy (SMD 6.52, 95% CI 4.75 to 8.30, p<0.01) and tenocyte-like cell injections (SMD 4.08, 95% CI 2.92 to 5.25, p<0.01). Those results should not send anyone shopping for a miracle injection. Polidocanol's effect size was an outlier in the network and may reflect small-study bias, selected patients with neovascularization, or protocol differences. Tenocyte-like cell treatment requires specialized culture infrastructure and is unavailable in most clinical settings.

The meta-analysis did find a statistically significant VISA-P result for LP-PRP combined with high-volume image-guided injection (HVIGI): SMD 1.56, 95% CI 0.62 to 2.50, p<0.01. But a combination result cannot identify which component did the work.

The direct test: PRP versus dry needling

The most clinically relevant trial is a 2024 multicenter randomized controlled trial by Herrero et al. It enrolled 31 people with patellar tendinopathy who had failed conservative management. Participants received either ultrasound-guided LP-PRP plus eccentric exercise or dry needling plus eccentric exercise. The study followed outcomes at 12 and 26 weeks.

No between-group difference reached statistical significance at either time point for VISA-P, pain, Lysholm score, VR-12 quality-of-life score, or Tegner activity scale. At 12 weeks, the numerical VISA-P improvement favored dry needling: 28.4±19.4 points versus 19.2±15.9 points with LP-PRP. Pain improvement also numerically favored dry needling, −2.8±1.9 versus −1.58±2.1 on the visual analog scale.

By 26 weeks, the dry-needling group had a statistically significant within-group VISA-P improvement from baseline (22.0±14.6, p<0.05); the LP-PRP group did not. LP-PRP participants did show significant within-group improvements in Lysholm score and pain at 12 weeks, with those improvements persisting at 26 weeks. The relevant comparison, however, is between groups receiving the same eccentric exercise program. On that test, PRP did not demonstrate an advantage.

The trial was designed to test whether LP-PRP was superior, not whether the two treatments were equivalent. About 23 of 31 enrolled participants completed all follow-up assessments, a dropout rate of roughly 26%. A study this small could miss a modest difference. Still, dry needling trended better across the reported outcomes and time points, which makes a large added benefit from LP-PRP less plausible.

Maybe the needle is doing more than the platelets

Dry needling and tendon fenestration mechanically disrupt tissue. That may create local microhemorrhage, alter painful neovascular tissue, and trigger an endogenous repair response. These are proposed mechanisms, not proof that any one procedure repairs a tendon better than another. Yet they offer a credible explanation for why adding externally concentrated platelet factors may fail to move functional outcomes.

The HVIGI result needs the same caution. HVIGI uses a large volume of fluid under ultrasound guidance around the tendon, intended to mechanically separate or strip neovascular and nociceptor-bearing peritendinous tissue. In a double-blind 2022 trial by Barker-Davies et al. involving Achilles and patellar tendinopathy in active military personnel, the procedure provided the relevant mechanical context for interpreting injectate-based claims. LP-PRP plus HVIGI may work because of the high-volume mechanical procedure, because of PRP, or because of both. The available evidence does not isolate PRP's contribution.

A separate biological test points in the same direction. In a 2021 double-blind, placebo-controlled trial by Olesen et al., local IGF-1 injection added no benefit to heavy slow resistance training for patellar tendinopathy over one year. IGF-1 is among the growth factors proposed to contribute to PRP's effects. A null trial of one growth factor does not settle the question for the whole PRP mixture, but it weakens the claim that simply adding growth factors to a loading program reliably improves this tendon.

Why the biology still has supporters

LP-PRP is not irrational. It concentrates platelet-associated factors such as TGF-β, PDGF, IGF-1, and VEGF while limiting leukocytes, which may reduce exposure to inflammatory mediators such as IL-1β and TNF-α. A 2024 review by Bosco et al. describes that rationale and reports positive findings in selected trials. PRP preparation varies widely, however: platelet concentration, activation method, injection volume, number of injections, rehabilitation timing, and exercise co-interventions differ across studies. "LP-PRP" describes a family of procedures, not one standardized treatment.

There is also no direct LP-PRP-versus-leukocyte-rich PRP randomized trial for patellar tendinopathy in this evidence base. The preference for leukocyte-poor preparations is mechanistic, not a clinically validated head-to-head result.

Selected populations may respond differently. A preliminary 2021 double-blind trial by Rodas et al. reported improvement with LP-PRP in chronic patellar tendinopathy with a structural gap larger than 3 mm. That is a narrow, severe subgroup and cannot establish benefit for the typical recreational athlete or jumping-sport participant with patellar tendon pain.

Loading remains the center of treatment

Progressive tendon loading—eccentric exercise or heavy slow resistance training—has the strongest practical role in rehabilitation. A 2025 analysis by Deng et al. examined possible mediators of progressive tendon-loading exercise in athletes with patellar tendinopathy, comparing it with eccentric exercise in a randomized-trial dataset. The study reinforces the field's focus on loading programs, although it does not make every exercise protocol interchangeable.

The broader PRP literature does not rescue the patellar-tendon evidence. A 2025 systematic review by de Sire et al. found mixed and inconsistent PRP results across injured athletes, with heterogeneous preparations and injury types preventing firm conclusions. Results from a rotator cuff, an Achilles tendon, or a knee joint cannot be assumed to apply to the patellar tendon.

What to do with this evidence

LP-PRP can reduce pain modestly in the medium term, but current randomized evidence does not show that it improves patellar-tendon function more than dry needling or loading-based rehabilitation. No injection strategy in the 2025 network meta-analysis demonstrated a benefit beyond six months, and longer-term data are sparse.

For someone deciding whether to pay for LP-PRP, the honest answer is: it is an optional adjunct with uncertain functional upside, not a proven shortcut past progressive loading rehabilitation.

If a clinician recommends PRP, ask which preparation they use, how it differs from other protocols, what loading program accompanies it, and what evidence supports that exact approach. A sensible plan should also account for diagnosis, symptom duration, tendon structure, sport demands, and alternatives such as supervised progressive loading. The burden of proof for LP-PRP's added value over needling has not yet been met.